AHA 2018
While the use of NSAIDs was low in the ARISTOTLE trial, NSAID users had a higher risk for bleeding than non-users.
News
The researchers found the risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban.
News
Different factor concentrates can reverse some of the alterations in hemostasis attributed to apixaban.
News
Lower rates seen for ischemic stroke or systemic embolism, GI bleeding or intracranial hemorrhage.
News
Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is safe and well tolerated.
AHA 2015
Older patients, females, and those with comorbidities were more likely to be on multiple medications.
Drugs in the Pipeline
Portola Pharmaceuticals, Bristol-Myers Squibb Company, and Pfizer announced results from the Phase 3 ANNEXA-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors - Apixaban) study with andexanet alfa as a reversal agent for Eliquis (apixaban).
News
Apixaban is more effective than aspirin in reducing the risk of repeat stroke and systemic embolism in patients with atrial fibrillation (AF) who are unsuitable for vitamin K antagonists (VKA) therapy.
News
Compared with warfarin, apixaban was correlated with reduced risk of major bleeding and intracranial bleeding (adjusted hazard ratios, 0.66 and 0.4, respectively) and dabigatran was correlated with reduced risk of intracranial bleeding (adjusted hazard ratio, 0.45) among patients with atrial fibrillation.
AHA 2015
Researchers conducted a post hoc analysis of the ARISTOTLE trial which included patients with atrial fibrillation (AF) and a risk of stroke treated with either apixaban or warfarin for the prevention of stroke/ systemic embolism.